Key Highlights
- HeartBeam appoints Timothy Cruickshank as Chief Financial Officer (CFO), effective immediately.
- Cruickshank brings over 15 years of public company experience in driving financial growth and governance.
- He succeeds long-time CFO Richard Brounstein, who retired in February 2024.
- HeartBeam’s innovative 12-lead ECG technology is under FDA review, with 13 US patents supporting the platform.
Source: Business Wire
Notable Quotes
- “Tim has an outstanding record of delivering results and creating value and will be a strong partner in ensuring we have a solid financial position as we strive to make our vision to transform the monitoring and detection of cardiac conditions a reality.” — Branislav Vajdic, PhD, CEO and Founder at HeartBeam
- “The ability of HeartBeam’s unique technology to unlock actionable heart intelligence from three dimensions for a range of cardiac conditions is truly compelling to me.” — Timothy Cruickshank, CFO at HeartBeam
SoHC's Take
The appointment of Timothy Cruickshank as CFO signals a strong focus on growth and innovation for HeartBeam. His impressive track record at ImpediMed, transforming it into a SaaS-based medical technology company, aligns well with HeartBeam’s vision of redefining cardiac care. With the FDA review of its revolutionary 12-lead ECG device underway, HeartBeam appears to be positioning itself for significant advancements in patient care through mobile and portable cardiac monitoring technology.
